Dynamic Antigen Expression and Intrinsic CTL Resistance in HIV Reservoir Clones.
| Publication Type | Preprint |
| Authors | Ferreira I, Herrera A, Huynh T, Board N, Stone E, Linden N, Ren Y, Bittar C, Pal V, Vedova S, Naing E, Sinha P, Danesh A, Ovies C, Liu F, Leyre L, Canis M, Teixeira A, Moir S, Chun T, Kovacs C, Zumbo P, Betel D, Halvas E, Lee G, Caskey M, Bieniasz P, Nussenzweig M, Jones R |
| Journal | bioRxiv |
| Date Published | 02/23/2026 |
| ISSN | 2692-8205 |
| Abstract | Reservoirs of clonally expanded CD4 + T-cells harboring rebound-competent HIV proviruses persist lifelong during ART. Latency is considered the principal barrier to viral eradication and has resisted pharmacological reversal, yet it appears that sustained immune pressure may still erode reservoirs. Recent advances have yielded glimpses into these exceptionally rare reservoir-harboring cells, implicating intrinsic pro-survival properties in their persistence. Here, we isolate and characterize populations of authentic reservoir clones (ARCs) that robustly proliferate and accumulate while producing infectious virus, without overtly succumbing to viral cytopathic effects. At any given moment, only small fractions of ARCs expressed HIV proteins, a state remarkably unperturbed by potent TCR or mitogenic stimulation. Nevertheless, sustained co-culture with cytotoxic T-lymphocytes (CTL) revealed extensive time-integrated antigenic vulnerability, culling clonal expansion of some ARCs by >90%. Notably, a regulatory T-cell ARC displayed pronounced cell-intrinsic resistance to CTL - a longstanding hypothesis we now directly demonstrate - linked to low oxidative stress and reversed with desferoxamine, a hypoxic stress inducer and FDA-approved therapeutic. Overall, we provide novel insights into the vulnerabilities of reservoir clones to potent, sustained CTL pressure and highlight intrinsic resistance pathways as actionable therapeutic targets, opening opportunities for advancing immune-based HIV cure strategies. |
| DOI | 10.64898/2026.02.22.707300 |
| PubMed ID | 41809016 |
| PubMed Central ID | PMC12970335 |